Trials: Leukemia

You are here:

Find a Clinical Trial
Leukemia

Gut Microbiome in Acute Leukemia and Allogeneic Stem Cell Transplant Patients

August 12, 2025

NCT04161885 – A Randomized, Open Label Phase 3 Study Evaluating Safety and Efficacy of Venetoclax in combination with Azacitidine after allogeneic Stem Cell Transplantation in Subjects with Acute Myeloid Leukemia (VIALE-T)

August 12, 2025

NCT04400591 – Expanded Access Protocol (EAP) for Patients Receiving Lisocabtagene Maraleucel that is Nonconforming for Commercial Release

August 12, 2025

NCT04637763 – A Phase 1, Multicenter, Open-Label Study of CB-010, a CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy in Patients with Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)

October 30, 2025

NCT05554406 – MM1YA-S01, “A Randomized Phase II Study Comparing Cytarabine + Daunorubicin(7+3) vs (Daunorubicin and Cytarabine) Liposome, Cytarabine + Daunorubicin +Venetoclax, Azacitidine + Venetoclax, and (Daunorubicin and Cytarabine) Liposome+ Venetoclax in Patients Aged 59 or Younger Who are Considered High-Risk(Adverse) Acute Myeloid Leukemia as Determined by MYELOMATCH; AMyeloMATCH Clinical Trial”

October 30, 2025

NCT06337318 – S2308 Randomized Phase III Study of Mosunetuzumab vs. Rituximab for Low Tumor Burden Follicular Lymphoma

October 30, 2025

NCT06337318 – S2308 Randomized Phase III Study of Mosunetuzumab vs. Rituximab for Low Tumor Burden Follicular Lymphoma

November 24, 2025

NCT06852222 – A Phase 3 Randomized, Double-blind, Placebo-controlled, Study of BLEXIMENIB, Venetoclax and Azacitidine for the Treatment of Participants with Newly Diagnosed Acute Myeloid Leukemia Harboring KMT2A Rearrangements or NPM1 Mutations who are Ineligible for Intensive Chemotherapy

October 30, 2025